NASDAQ:BLRX
BioLineRx Ltd. Stock News
$0.575
-0.0377 (-6.15%)
At Close: Apr 25, 2024
BioLineRx Ltd. to Host Earnings Call
12:00pm, Wednesday, 20'th May 2020
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / BioLineRx Ltd. (NASDAQ:BLRX) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 20, 2020 at 10:00 AM Easte
BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
11:00am, Wednesday, 20'th May 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended March 31, 2020 and provides a
BioLineRx to Report First Quarter 2020 Results on May 20, 2020
11:00am, Friday, 15'th May 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended M
20 Healthcare Stocks Moving In Monday's Pre-Market Session
11:39am, Monday, 13'th Apr 2020
Gainers
• Biocept, Inc. (NASDAQ:BIOC) stock moved upwards by 55.72% to $0.56 during Monday's pre-market session.
• BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock...
Stocks To Watch: 0% To The Rescue?
12:49pm, Saturday, 14'th Mar 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
11:00am, Thursday, 12'th Mar 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended December 31, 2019 and provides a
BioLineRx to Report Annual 2019 Results on March 12, 2020
01:00pm, Friday, 06'th Mar 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended Decemb
BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent
BioLineRx Concludes Recruitment in Pancreatic Cancer Study
04:44pm, Thursday, 23'rd Jan 2020
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
BioLineRx Concludes Recruitment in Pancreatic Cancer Study
12:00am, Thursday, 23'rd Jan 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its o
